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A multicenter study was performed to determine the Incidence of
adverse reactions to two contras) media with similar low osmota .
lity during cardiac anglography . The study was of a randomized
double-blind design comparing loeagtate (an ionic turner) and
iopamidol (a nonionic compound) and included 500 patients ; 250
patients received ioaaglale and 250 inpamtdnl . There were 5R
adverse rearlinmn athibitleti to the contrast media in lbe
ioeaglate
group and 29 In the iopamidol group (p < 0.001). Chest pain
averred in 11 patients in the ioxaglate group compared with 5 in
the iopamidol group (p =0.133), Nausea or vomiting was present
in 20 and 2 patients, respectively (p < 0.0002) .
Allergic adverse reactions, such as brmwhmpmm, articaeia
and itching, occurred in 15 of the ioxaglale group and only I of the
patients receiving iopamidol (p < 0 .0007) . Fifty-two patients in
Many of the adverse reactions encountered during cardiac
angiography are directly related to the contrast medium
(I .2). Ideally, this medium should provide adequate radio-
graphic opacity without any physiologic or pharmacologic
effects. It is well recognized that intracardiac injections of
the standard contrast media are often associated with elec-
trophysiologic changes and a decrease in arterial pressure
and in myocardial contractility (I-5) . Chemotoxic effects,
such as peripheral pain and warmth, and allergic reactions
also occur (1,2) . The factors that may be responsible for
these adverse reactions include hyperosmolality, the sodium
and calcium content and the anion or molecular composition
of the contrast medium (1-10). Although the osmolality, of
the contrast medium is not the only factor, it is a very
important determinant of the cardiovascular and chemotoxic
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the toxaglate group had a known allergic history (not to contrast
medium) or asthma, whereas 77 receiving iupanfidOt had a similar
history . Seven tithe 52 loeaglate-Irealed patients developed an
allergic adverse reaction compared with none of the 77 in the
!upamidul group (p = 0.001). Of 41 patients recrtvlag btxaglate
who were prrmedirated with diphenhydomine, d had an allergic
-4,-wt.
lathe iopamidol group 45 patients received similar
premedication and none had an allergic adverse reaction (p <
0 .121.
Thus, this multicenter study shows that adverse rewfiens
occur more anew with tuxagtale than with iupamidet and "rat
patients with an allrge hi story have a greater rids with invagtale
therapy
compared
with iopamidol.
(J Am Call Cmdiol 1992 ;19:399-906)
side effects (1,3,4,11,12) and may also play a role in allergic
reactions (1
During the past 2 decades there has been an active search
for new radiographic contrast compounds to eliminate the
cardiovascular side effects and chemotoxicity . To decrease
die osmolality of the contrast medium, an effort has been
made to increasethe number of iodine atoms per osmo€ically
active panicle. In 1973 ioxaglate was synthesized (18). It is a
structural dinser with six iodine atoms to one anionic func-
tional group, as compared with the conventional diatrizoate
molecule . which has only three iodine atoms to one anionic
group . Other
efforts to reduce osmolality have led to the
development of nonionic contrast media
. Conventional con-
trast media are ionic compounds with cation and anion
particles in solution ; nonionic compounds reduce their os-
molality by having only one particle in solution for a given
iodine content, The first noninnic contrast medium, metri-
zamide . was introduced in 1974
(19) . Melrzamide has two
major disadvantages : it is not heat stable and not stable in
solution ; therefore, it must be reconstituted from the lyoph-
ilized form immediately before intravascular injecliun . Mum
recently the motivate compounds iopamidol, iohexol and
ineersol have been developed and released for clinical use,
These compounds are very stable in aqueous solution .
Large multicenter studies (20-22) have shown that the
arsa .lo,rtsvss.eo
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incidence of severe and moderate adverse reactions is sig-
nifeantly less with the intravenous use of the low osmolalit y
nonionic contrast media than c0 he conventional high osmo-
lality ionic contrast media . The ionic dimer ioxaglate was nut
included in these multicenter trials because its intravenous
use is 2=sociated with a high incidence of vomiting !20,22) ;
however, ioxaglate is widely accepted for intraarterial pro-
cedures. Because the published studies (23-25) comparing
the low osmolality ionic direr with nonionic contrast me-
dium were performed at single institutions and included only
a small number of patients, the true incidence ufthe adverse
reactions may be questioned
. Therefore, this multicenter
study was performed to evaluate the adverse reactions
associated with the low osmolality ionic dieter ioxaglate and
the nonionic monomer ioparnidel during intraarterial cardiac
and coronary injections .
Methods
Study design. The study was eta prospoelive randomized
double-blind design for comparing the combination of icx-
aglale meglumine, 39 .3% and ioxaglate sodium, 19 .6%
(Hexabrix) with iopamidol, 76% (lsovue-370) as contrast
media used for left ventricuiography and selective coronary
angiography . Twelve medical centers (nine in the U .S. and
three in Canada) participated . Randomized lists for the two
contrast media were generated by Squibb Diagnostics . The
technician or nurse in the laboratory selected the contrast
medium from commercially available lots . The patients, the
physicians (investigators) perfuming the study and the
investigators analyzing the data did not know which contrast
medium was used .
Patient selection, Men or women 018 years of age who
required coronary angiography and left ventriculography for
clinical diagnostic evaluation were candidates for this study
.
Patients with the following conditions were excluded from
the study: I) pregnancy, childbearing potential or current
breast feeding; 2) a history of a previous reaction to radio-
graphic contrast medium or iodine compounds ; 3) a bleeding
disorder; 4) significant renal disease (serum creatinine
>2 mg/dl) ; 5) phcochromocylema, sickle cell disease, mul-
tiple myeloma or parapruteinemin; 6) significant hepatic
disease (bilirubin >2 mg/100 ml) ; 7) infection near the
proposed site of catheter introduction ; 8) acute myocardial
infarction and scheduled streptokinase therapy or percuta-
neous translumimd coronary angioplasty ; 9) known signifi-
cant mitral or aortic valve disease; 10) significant primary
cardiemyop[hy ; II) a permanent pacemaker ; 12) atrial
fibrillationllulter or frequent premature atrial or ventricular
depolarization (>3/min) ; 13) left bundle branch block ; 14)
electrocardiographic (ECG) evidence of left ventricular hy-
pertrophy with strain pattern ; 15) weight >160 kg ; and 16)
previous entry into this study or current participation in a
clinical trial of an investigational drug .
Study protocol . The protocol was approved by the Hu-
man Research Committee at each of the 12 medical centers
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and informed written consent was obtained from each pa-
tient before the procedure
.
Procedures
. A brief cardiac history, a list of other con-
comitant illnesses and an allergic history were required for
entry into the study. All medications received before or
during the procedure were also recorded as part of the study .
No dosage of any medications prescribed for the treatment
of augiua or other illnesses was withheld before the cathe-
terization procedure . Sedation with diazepam and other
agents administered for premeditation were prescribed by
the physicians performing the procedures . It was recom-
mended that 5,000 U of heparin be given to all patients at the
time of the arterial puncture .
The ECO and arterial pressure were monitored continu-
ously during the entire procedure. All patients underwent
left ventriculography and selective injections of the right and
left coronary arteries and bypass grafts, if present . For the
left ventnculogram. 0.5 ml/kg of contrast medium was used,
The sequence of the injections was determined by the
physicians performing the catheterization . The amount of
contrast medium used and the time and the site of every
injection were recorded . As part of the study protocol, the
ECG was also recorded before, during and continuously for
the Ist 2 min after the first right coronary artery injection,
the first left coronary artery injection and the left ventricu-
Ingram .
Atthe end of the procedure, the patient was asked, "How
did you feel during this study?" Questions concerning spe-
cific adverse reactions such as pain or nausea were not
asked. All adverse reactions (such as symptoms or clinical
manifestations of an embolic event, chest pain, dyspnea,
arrhythmias, nausea, vomiting, bronchospasm or urticaria)
noted by the investigators or reported by tho patients and the
treatment, if any, of these conditions were recorded . The
investigators were asked to grade the adverse reactions as
mild (resolving spontaneously without treatment), moderate
(requiring medication or other treatment but not additional
hospitalization) or severe (requiting additional hospitaliza-
tion and treatment) and to state if the adverse reaction was
secondary to the contrast medium. Adverse reactions that
occurred during or after injections of contrast medium and
were not related to procedural techniques or other medica-
tions were attributed to contrast medium .
Statistics. The unpaired r test was used to compare
baseline values between the two patient groups, and the
Chi-square test was used to compare discrete variables (26) .
The data in the text and tables arc presented as mean values
'_ISD
.
Results
Of the 500 patients included in this randomised mulli .
center study, 2311 received ioxaglate and 250 received iopa-
midol . As shown in Table I, patient chars neristics of the
two groups were similar except that the number of patients
1,1C Vol . It, No. 5
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Table 3 . PoGcnls
With Asthma or History of Any Allergy .
'or Both
Dab refer to number of patients airless otherwise Indicaled . CARL =
rm,®ry artery hypos grab ; CAD =
cursory anery disease:CM
=
00pemat
medium: MI = ocardial iafaaen- NS = nut significant, RCA = right
coromry anory : V D = vessel dittos:.
with a history of allergy was significantly higher in the
iopamidol group (p = 0 .01) .
Adverse reactions (Table 2) . Sixty-seven patients in the
iexaglate group had 02 adverse events during the catheler-
ization procedure, whereas 40 patients in the iopamidel
group had 50 adverse events (p < The adverse events
attributed to the contrast medium were 58 in the ioxaglale
group and 29 in the iopamidol group (p < 0
.11) (Table 2) .
Except for the sensation of mild womth associated with an
injection, the incidence of ail other adverse events listed in
Table 2 was higher in the ioxaglate group than in the
iopamidal group . All the adverse reactions attributed to
contrast medium were classified as mild or moderate with
the exception that one of the two cases of bronchospasm was
graded as severe .
There were no deaths, serious ventricular arrhythmias,
pulmonary edema or embolic events in either patient group.
Heparin was given to all patients in this study ; 452 patients
received 5,000 U of heparin at the beginning of the proce-
dure, 38 patients received heparin doses of 2,000 to 10,000 U
Table 2 . Adverse Reactions Attributed to Contrast Medium
	Allersic-lype adverse reactions . ADR = adverse reaction, CM = con.
seas. medhrtn .
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CM = casinos medium .
(mean 4,900 U) and 10 patients had received anlieuagulant
therapy with intravenous heparin for clinical indications
before the catheterization
. The dosage used to maintain
therapeutic partial thraarboplastin levels was continued
throughout the agiographic procedure .
No patient in this study required cardiac pacing and there
were no reports of heart block or significant hradyarrhyth-
mias attributed to contrast medium . Only 6 of the 500
patients (2 in the ioxaglate group and 4 in the iopamidol
group) received atropine, which was given as premedicalion
or for a vagal episode that occurred during the arterial
puncture.
Ilventy patients in the ioxuglate group had nuusea ur
vomiting. whereas only 2 patients in the iopamidol grown had
nausea . In the ioxaglate group, 7 of the 96 patients who
received the initial injection of contrast tncdiaa during :efl
ventricolography developed nausea or vomiting compared
with 11 of 153 patients who had the ventriculogram at the
end of the procedure (p = 0.73) . Thus, timing of the left
ventriculogram, which requires a relatively large bolus in-
jection, at the beginning or at the end of the procedure did
not affect the incidence of this adverse reaction in ionagtale-
treated patients.
In this report allergic-type adverse reeveors included
itching, rash, urticaria, bronchospasm or aaaphylacloid
shock. No patient in this study developed anaphylactoid
shock. There were 16 allergic adverse reactions in the 250
patients receiving ioxnglare compared with 4 such responses
in the 250 patients receiving iopamidol (p < 0 .01). Of these
allergic rdscrse reactions, 15 of the 16 in the ioxaglote group
were attributed to the contrast medium compared with only
I of the 4 in the iopamidol group (p < 0 .0007) (Table 2). The
remaining four allergic adverse reactions were attributed to
protamine; all four such reactions involved a rash or or-
ticaria and occurred within 5 to 15 min after intravenous
administration of protamine. These events were attributed to
the medication administered by the patient's physician .
History of allergy (Table 3)
. Patients with a previous
history of a reaction to radiographic contrast medium or
iodine compounds were excluded from this study . However,
in the iopamidol group 77 patients reported a history of other
allergic responses: 3 had asthma, 72 had drug allergies, 2 had
foodallergies, 2 had potlinosis and 2 had allergies to insect
bites or stings. In the ioxaglate group 52 patients had a
Iopam7dol loxaglale p Value
Total so. attributed toCM 29 58
0
.001
Cheer pain
11
0.123
Nausea 2
16 0.001
vomiting
0
4 6142
Itchingleas(arrticaria' I 13 0.002
Broncho:pasm' 0 0.153
Warmth 21
11 0
.064
Bed taste 0 1 0.318
lopamidal Iosagla!e p Value
No, or pea=r's 750 750 NS
Ant (yo 6O = I? 59 = II NS
Makikmak ratio 172<1 192150 NS
Previous Ml
02 5
97 NS
PreriovaCABC 20 21 NS
CAD
O9D 46 5ft NS
I VD Fit 59 NS
2VD 50 64 NS
3 VD a5 77 Nt :
Lcn rearloos,1„0^x1 I4
16 N5
11079 RCA O¢h,isrn
49 51 NS
Rjcchon Dart- IR
.1
64 13 61 - 14
NS
Diaberesmellhas 33 34 NS
History ofallergynra4hm . 77
52 0 .01
Total amount
of CM Injected (ml) 100- 34 101 c 28 NS
105550301 105550 e p Value
Talal no- r:i,h asthma or his-
of energy
77 5.. 5.510
No ,. . .n Al,-,.- adverse
achnn attnhntcd In CM
0 O. MI
rc lmringlrashlurticana
A~oactospasm
0
D
6
I
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Table 4 . Type,
of Premedictrion and Adverse Events in
similar history: 5 with asthma, 44 with drsrg allergies, I with
food allergy, I with pollinosis and 2 with allergies to insect
biles!stings .
None of the 77 patients in the iopamidol group with a
history of allergy had an allergic-typo adverse event attrib.
uted to the contrast medium . compared with 7 of the 52
patients in the ioxaglale group with such a hiv,ery (p =
0
.001) (Table 3) . Thus, the incidence of an allergic adverse
event in the patients receiving ioxee late was significantly
higher in those with a history of allergy (13 .5%) than in the
total group (b%) (p = 11 .111 1). Despite o significantly greater
number of patients with a history of allergy in the iopamidol
group, the incidence of
allergic-type
adverse events re-
mained very law 10.4% in the total group and 0% in the group
with a hste,p nlallergy)
.
3':emcdication(Table 4)
. Thepharmacotagicugentscom-
mainly used for premedicntion, as well as the adverse events
in each group, are listed in Table 4
. There was no difference
between the two patient groups in the number of patients
who received any of the specific agents used for premcdica-
tion
. The number of patients inking each of these agents is
too small to permit definite conclusions about the efficacy of
premedication . However, the data suggest that pretreatment
with diphenhydramine o,^ sedation with diazepam will not
prevent an allergic adverse reaction with ioxaglale .
JACC Vul 19, No 5
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ISCG changes. Two hundred thirty-four ECG recordings
from seven of the medical centers were analyzed The ECG
data before and immediately after the first right cur-nary
artery injection were as follows : the mean RR interval was
0 .07 ± 0.13 s before and 0.95 t 0 .14 s alter (p = NS) the
eee(rast injection in the ioxaglale group and 0.94 ± 0.15 s
and 0 .94 ± 0 .16 s (p = NS(
. respectively, in the iopamidol
group . The mean QT interval before the itjection was 415
.
43 ms in the iunaglate group and 423 ma 44 ms in the
iopamidol group . Immediately after the contrast injection,
the maximal QT interval change was i 40 a 42 ma in the
ioxaglale group compared with only +4 s 36 nas in the
iopamidot group (p
c
0.0001). Similar FCG changes were
observed with the left coronary artery injections .
Discussion
Adverse reactions during aagiagraphy . This was the first
multicenter study to compare in a prospective, randomized
and blinded fashion the adverse reactions to ionic and
nonionic contrast media with similar relatively low osmola-
lity administered during cardiac angiography. The incidence
of mild to moderate adverse reactions was significantly
higher with the ionic dinner (ioxaglale) than with the nonionic
compound (iopamidol). Among the 500 patients studied,
there were no deaths, serious ventricular arrhylhmias or
embolic events
. Two patients in the ioxaglale group devel-
oped bronchospasm; one of these adverse events was clas-
sified as severe and the other as moderate . No severe
adverse reactions were reported in the lope midultreated
patients.
MultiveMer trials far intravenous prnaedures- Large mnl-
ticenter studies (20-22) have Compared the adverse reac-
tions associated with the intravenous administration of
nonionic with ionic contrast media . Palmer (20) performed a
prospective survey
of reactions to Intravenous contrast
medium injections in multiple hospitals and private practices
in Australia and New Zealand; 109,546 cases were included.
The incidence of adverse reactions in high risk patients
receiving ionic contrast medium was 10.3% compared with
1 .3% in the high risk patients receiving a
nonionic
medium
(p < 0 .00l) severe reactions were 0 .3690 and 0,03% . respec-
tively (p < 0.001) . In a similar intravenous study conducted
in Japan, Katayama ct al. 122) reported an 337,647 cases . In
that study the overall incidence of adverse reactions was
12 .7% for ionic contrast medium and 3
.1% for nonionic
medium, whereas that of severe adverse reactions was
0.26% and 0 .04% inn the respeucivc gmuvs, those siudies
were not randomized or blinded and the number
of patients
receiving nonionic contrast medium was significantly greater
in the high risk groups. Despite the limitations, these studies
clearly show that the incidence of adverse reactions assuci-
etled with the intravenous use of nonionic contrast medium is
significantly less than with the ionic contrast medium. The
ionic contrast media in these studies were all ionic mono-
mers with high osmolality compared with that of the
500 Patients
Iapaaido : taaagacte p value
Diazepam 193 192 VS
All ergictype tdeere reaction
Neosea/snmitiog
I
1
p .0el
DipSerhydraetiae 45 4s
Atergic-lype ad mcmi react a, 4 0 .03
Naanaknmiting
H,-recepterareaean$t.,
0
32
I
77
VS
VS
:Jiuys-type ad>e- caHkn
PitaEeyconltling
e
0 2
PS
NS
Steroids 2 2 N9
Allerv .Ipra: alearse reaction 0 0 N9
Naaseatvpmitint 0 0 NS
Diazepam and dipheahydvaree 25 ;9 N9
dhngk-type aJvese leaSi , u 3 004
N neereetdti
0 I N5
DiveepamcadX rstep :aeaMagaoisla 21 N5
Alhrsic-type
.1 .- -Ii-
NeusaNnmihng
Diptcnhydmmine-111_"toe,ri,r
a
0
Id
I
16
NS
NS
NS
annegonisis
allcrgk type edvc,,ac rcaetnn
Na,rseahnreilhe
Diazepam . dlihenhydramine and H,
n
I
7
a
I
10
Ns
Ns
V9
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Allergic type adrerereulian a 0 VS
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nonionic monomers such as iopamidol and iohexol lox-
aglate, an ionic dimer, has a relatively low osmolality
comparable to that of iopamidol and iohexoL However.
because of the high incidence of nausea and vomiting asso.
dated with intravenous injections of ioxaglate, it was not
included in the reported studies 129,221 Thus, the question
remains whether many of the adverse reactions are related to
the high osmolality o€the conventional ionic contrast media
or to the ionic nature of the compounds .
loangl de is widely used for arterial urigiographv . In
addition, several reports (27,28) have stated that the inci-
dence of adverse reactions differs between intravenous and
intraarterial angiography . Thus, the present study was per-
formed to compare ioxaglate and iopamidol during cardiac
angiography. Our findings agree with those of the large
multicenterintravenous studies : that is- the incidcncc of the
adverse reactions is significantly higher with ionic than with
nonionic contrast media
. Because both contrast media in our
study had similar osmnlality, our data suggest that the
molecular structure may play an important role in determin-
ing the side effects of the contrast media .
Adverse cardiac effects. The side tTectsofcontrasit media
during cardiac angiography can be classified as cardiac,
hemodynamic or systemic. In the present study we observed
that the QT interval prolongation immediately after the
coronary injection was more significant in the ioxaglate than
in the iopamidol g roup. ST segment and T wave changes
were also observed in the ioxaglate-treated patients : how-
ever, because placement of the ECG leads was not uniform
in this multicenter study, it was not possible to quantitate
changes in these variables . Other studies 123-25) have also
reported that the ST segment, T wave changes and QT
interval prolongation are significantly greater with ioxaglate
than with nonionic contrast medium . The origin of these
ECG alterations redlaius uncertain. 'I he results of several
laboratory studies (5-7,29) suggest that the calcinm-
chelating properties of the contrast medium may be an
important fadvr associated with these ECG changes . The
significance of these changes is also not known . Studies in
animals (5,30,31) have shown that the ventricular fibrillatory
threshold is inversely related to the QT interval prolongation
after contrast medium injections . However . no patient in our
study had ventricular tachycardia or fibrillation, With the
conventional ionic contrast media, the incidence of this
adverse event varies from 0 .6% to 13% (32.33)
. Thus, these
data suggest that the incidence of serious ventricular ar-
rhythmias may even be lower for both iopamidol and iox-
aglate .
Selective coronary angiography with the conventional
ionic contrast media is often associated with bradyarrhyth-
rnias and heart block (1,11,34,35)
. No significant bradyar-
rhythmias attributed to contrast medium or heart block were
reported in this study . This finding agrees with (hose of
previously published reports (11
.23-25,34) from relatively
small trials at single institutions ; that is, coronary injections
GFRT7. FT Al -
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of nonionic contrast mrrhcm or ioxaglate are not associated
with significant increases in RR intervals .
Hnoadrnumic r rrabfes and
mw,-dial
contmrtility
mere not measured in this study . However, there were no
reports of pulmonary edema or significant hypotension dur-
ing or immediately after the procedure . The osmnlality, of the
contrast medium appears to play a major role in the hemo-
dynamic alterations, such as transient hypotension and
elevation of the left ventricular end-diastolic pressure that
occur after intraarterial injections of contrast medium
(1 .3 .wt .18.23 .5534-3b). Previous studies that have mea-
sured these hemodynamic indexes have shown that the
changes produced during bolus left ventricular injections are
similar for the nonionic monomers and the ionic dimer
inxaglnte and that these changes are minimal compared with
those induced by similar injections of the conventional ionic
monomer agents Q1,18,23,25,34,36-38) . Animal studies
(39 .401 assessing myocardial contractility have demon-
strated that the negative inotropic effects associated with
injections of the conventional ionic contrast media are
significantly less with ioxaglate and that the nonionic con-
trast media have a small positive inotropic effect .
Nausea and vomiting. Nausea and vomiting represent a
systemic chemotoxic effect of contrast media . A possible
explanation for this side effect is that the contrast molecule
binds to protein and results in enzyme inhibition of cholin-
eutcease (2,41,42)
. In vitro experiments (41) have shown that
nonionic contrast media such as iopamidol and iohexol
produce less inhibition of cholinesterase than does ioxaglate.
Intravenous injections of ioxaglate are often associated with
a high incidence (25% to 37%) of nausea and vomiting
(42-44) . to this intraartcriat randomized study, nausea or
vomiting, or both. occurred in 8% of the patients receiving
ioxaglate . In the iopamidot gr,m.tp, nausea only occurred in
0.81A (p
c
O,INJ03) . Other studies (21
.75,!5) that used iox-
aglate for intaarterial proCedates
have also reported a
higher incidence of [his adverse reaction.
Alle m rynn adverse reaclions, Allertdc-type or "anaphy-
lactoid" adverse reactions can be the most severe or life-
threatening adverse reactions that result from intravascular
injections of contrast medium- In this study two patients
developed brotlchospasm, classified as severe in one and as
moderate in the other ; loth patients were in the ioxaglate
group . No patient developed anaphylactoid shack or circula-
tory collapse . In addition to the two cases of brcnchospasm,
there were 13 other mild to moderate allergic-type adverse
reactions in the ioxaglate soup compared with only I in the
iopamidol group (Table 2) .
The eruct mechanism jar these allergic-type adverse
reactions it rtnrlear (46). The classic antigen-antibody im•
mane reaction has been postdated (47,48) but not proved .
Anticontrast medium antibodies have not been detected in
patients with adverse reactions (12) . Similarly, a high per-
centage of these patients do not experience recurrence of the
adverse reaction during subsequent angiographic procedures
(49). Contrast media can induce histamine and serotonin
904
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release (50,51) and can also activate the cimplement and
coagulation systems (17) . Contact-system activators are
present in vascular endothelium and mast cells ; release of
these activators by contrast media as well as other hyperos-
molar agents can result in a series of proleolytic events
leading to the production of bradykinins 115,521. Ialli and
(rcenslreet (16) hypothesized that many of the adverse
reactions are secondary to anxiety and are controlled by the
central nervous system. Whether one or several of these
mechanisms are responsible for the allergic-type adverse
reactions remains to be determined, However . the under-
standing of the pathuphysiolugy of these events may became
very important in the selection of or the future development
of contrast media .
Several clinical studies (22.27 .53-57) have shown that the
incidence of adverse reactions to contrast medium is two to
four times greater in patients with asthma or a history of any
allergy than in patients without these conditions . Among the
ioxaglate-treated patients in our study, 13 .5% of those with
asthma or a known allergy had au allergic-lyre adverse event
compared with 4% of those without these conditions . How-
ever, although more patients with a history of asthma or
allergy were receiving iopamidol, only one allergic-type
adverse reaction occurred in this group and the affected
patient had no known allergy . These data strongly suggest
that patients with asthma or a history of an allergy are at an
increased risk for an adverse event during angiography with
ioxaglate and that the use of a nonionic contrast medium
may reduce the risk in such patients . Several previous
studies (13-17) have implied that the high osmolality of the
contrast medium may be responsible for many of these
adverse events . However, the similar osmolality of the two
contrast media in our study suggests that the ionic nature of
the compound may play an important role in precipitctirg
these adverse events.
Premeditation with various phorinaealogic agents has
been advocated to reduce the risk of Ciese adverse events .
These agents include steroids 158.591, diphelhydramine or
H l -receptor antagonist (60), diazepam (16,61) and, most
recently, H,-receptor antagonist (62,63) . Controversy exists
as to the efficacy of these medications in reducing the
incidence and the severity of the adverse events induced by
contrast medium (49,1,63-66)_ In our study the number of
patients receiving premeditation did not differ significantly
between the immolate and iopamidol groups (Table 4) .
Although our study was not designed to assess the effects of
the various medications used for pretreatment, the data
suggest that pretreatment with diphenhydramine or seda-
tion with diazepam does not completely protect against an
allergic-type adverse reaction to ioxaglate . In addition, cases
have been reported (1,65,67,68) of severe anaphylaxis with
circulatory collapse occurring with the use of conventional
ionic contrast media and ioxaglate after premeditation with
diphenhydramine and steroids . Rapoport et al . 164) de-
scribed six patients who developed a severe anaphylactoid
reaction to conventional high osmolality ionic contrast me-
din despite premeditation ; several days after the untoward
event, these patients underwent repeat angiagraphy with use
of a nonionic contrast medium (metrizamide) and none of the
six had an adverse event with the nonionic agent, Hollas (68)
reported similar findings in 17 patients with a previous well
documented allergic-type adverse reaction occurring with
the use of conventional ionic contrast media; with iohexol as
the contrast medium only I of these 17 patients developed a
skin reaction that occurred very [are (that is, 24 h) after the
procedure
. These data suggest that the incidence of allergic-
type adverse reactions is signifcnntly lower with nonionic
than with ionic contrast media . Large randomized prospec-
tive studies are needed to determine whether the incidence
of adverse reactions with ioxaglate after pretreatment is
equal to or better than that with a nonionic contrast medium .
Clinical implications. This multicenter, prospective . ran-
domized study shows that ioxaglate and iopamidol are safe
and well tolerated during cardiac angiogimphy
. The incidence
of mild to moderate adverse reactions attributed to cottlcast
medium w,ix higher with the ionic dimerioxaglate than with the
nonionic contrast medium iopamidol. The alergic-type adverse
teato ionswere also higher in the ioxaglate-treated patients (6%)
than in the iopamidol
group (0
.4%) (p < 0
.0007). Among
patients treated with ioxaglate, those with asthma or a history
of a known allergy had a 3.4 times greater incidence of an
allergic-type adverse event than did patients without a known
allergy . None of the patients with asthma or a known allergy
receiving iopamidol had an allergic-type adverse event
. Thus,
these data suggest that a nonionic contrast medium should be
used for cardiac angiography to avoid allergic-type adverse
reactions, especially in patients with a known allergy .
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